Biodegradable micelles enhance the antiglioma activity of curcumin in vitro and in vivo

Songping Zheng1,*
Xiang Gao1,2,*
Xiaoxiao Liu1
Ting Yu1
Tianying Zheng1
Yi Wang1
Chao You1
1Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China; 2Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, USA
*These authors contributed equally to this work

Abstract: Curcumin (Cur), a natural polyphenol of Curcuma longa, has been recently reported to possess antioxidant activities. However, due to its poor aqueous solubility and low biological availability, the clinical application of Cur is quite limited. The encapsulation of hydrophobic drugs into nanoparticles is an effective way to improve their pharmaceutical activities. In this research, nanomicelles loaded with Cur were formulated by a self-assembly method with biodegradable monomethoxy poly(ethylene glycol)-poly(lactide) copolymers (MPEG-PLAs). After encapsulation, the cellular uptake was increased and Cur could be released from MPEG-PLA micelles in a sustained manner. The Cur-loaded MPEG-PLA micelles (Cur/MPEG-PLA micelles) exhibited an enhanced toxicity on C6 and U251 glioma cells and induced more apoptosis on C6 glioma cells compared with free Cur. Moreover, the therapy efficiency of Cur/MPEG-PLA micelles was evaluated at length on a nude mouse model bearing glioma. The Cur/MPEG-PLA micelles were more effective on suppressing tumor growth compared with free Cur, which indicated that Cur/MPEG-PLA micelles improved the antiglioma activity of Cur in vivo. The results of immunohistochemical and immunofluorescent analysis indicated that the induction of apoptosis, antiangiogenesis, and inhibition of cell proliferation may contribute to the improvement in antiglioma effects. Our data suggested that Cur/MPEG-PLA may have potential clinic applications in glioma therapy.

Keywords: curcumin, glioma, cell apoptosis, cell proliferation, angiogenesis

Introduction

An increasing number of patients have been diagnosed with glioma in USA over the past decades.1 More than a half of them are glioblastoma multiforme, which is one of the most malignant tumors of the brain characterized by high proliferation, migration, and aggression. Although major improvements have been made in standardized treatment, containing surgical resection, radiotherapy, and chemotherapy, the overall prognosis of glioblastoma multiforme is still very poor, with the median survival of ∼1 year after diagnosis.2–4 Chemotherapy should be the most curative method since surgery and radiation are restricted by permeation of tumor cells into normal brain tissues. However, the effectiveness of conventional chemotherapy is severely hindered since chemotherapeutic drugs are often eliminated in circulation and hard to reach a high local drug concentration in the tumor site. Moreover, the overexpression of multidrug resistance proteins by tumor cells causes efflux of various chemotherapeutic drugs.5–7 Therefore, new chemotherapeutic agents are sorely needed.

Curcumin (Cur), a natural polyphenol isolated from the rhizome of the plant Curcuma longa, is regarded to be nontoxic to humans since being part of the daily food of millions of Indians. It has been reported to possess anticancer property through various mechanisms, including cell cycle inhibition (suppressing cyclin D and inducing p21), differentiation induction (promoting autophagy), apoptosis promotion (activating...
caspase-3 and reducing bcl-xl), and anticancer drug resistance (targeting cancer stem cells).8-11 More significantly, studies showed that Cur selectively targeted tumor cells, leaving normal neural cells intact.12,13 However, due to its poor aqueous solubility, fast metabolism, and low biological availability, the clinical application of Cur is quite limited. Scientists have been developing different drug delivery systems that are expected to resolve the hydrophobic property, prolong the circulation time in blood, and increase the release to the targeted tissue, such as cyclodextrin complex, solid dispersion, phospholipid complex, and others.14-16 But there exist different problems in practice, such as highly unstable, less effective, or difficult for manufacturing.

Nanomedicine, which is an important branch of nanotechnology, has been rapidly developing in recent years. It is expected to play a vital role in early diagnosis and accurate treatment of diseases at molecular level. In the field of anticancer research, nanodelivery system has attracted much attention. Through the combination of drug and carrier, hydrophobic agents can be water soluble. Pharmacokinetics and biodistribution of drug could also be altered, so as to improve the bioavailability and specificity.17-19 Nanocarriers are mainly composed of silica, gold, iron oxides, liposomes, and polymeric nanocarriers, such as polyelectrolyte complexes, micelles, and hydrogels. Among them, biodegradable polymeric micelles are an attractive delivery system with nanoscale hydrophilic shell and hydrophobic core binding agents. The drug is combined with polymeric micelles through dissolution or by biodegradable chemical bond. The encapsulation of drug in the biodegradable polymeric micelles enables prolonged circulation time in blood, as well as preferred storage and effective control of drug release in the desired location with low toxicity.20-23

In this study, in order to improve the antiglioma efficiency, Cur-loaded monomethoxy poly(ethylene glycol)-poly(lactide) copolymers (MPEG-PLAs) were formulated by our group. We planned to explore the efficiency of these Cur/MPEG-PLA micelles at a cellular level by investigating the drug uptake, apoptosis, and cytotoxicity to tumor cells in vitro. More importantly, the subcutaneous tumor model in nude mice was used to evaluate the potential of this new delivery system to treat glioma in vivo.

Materials and methods

Materials

Dulbecco’s Modified Eagle’s Medium and fetal bovine serum (FBS) were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Cur and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Methanol and acetic acid (high-performance liquid chromatography [HPLC] grade) were purchased from Thermo Fisher Scientific. Dimethyl sulfoxide and acetone were purchased from KeLong Chemicals (Chengdu, People’s Republic of China).

MPEG(2000)-PLA(2000) diblock copolymer with a designed molecular weight of 4,000 Da was synthesized by ring opening of l-lactide, initiated by MPEG. MPEG (5.0 g) was melted in a 50 mL flask following the addition of anhydrous l-lactide (5.0 g) and Sn(Oct)2 (1 mL) under nitrogen. The mixture reactant was maintained at 125°C for 24 hours. The crude product was dissolved in tetrahydrofuran and then purified by precipitation in ice-cooled diethyl ether followed by filtration. This process was performed in triplicate, and the resultant product was vacuum dried at ambient temperature. The number average molecular weight (Mn) of MPEG-PLA copolymer was 4,010 Da (data not shown). The MPEG (molecular weight =2,000 Da) (Sigma-Aldrich Co.) was dried in a one-necked flask under vacuum and magnetically stirred at 105°C for 90 minutes before use.

The C6 and U251 cells (obtained from American Type Culture Collection [ATCC], Manassas, VA, USA) were cultured in Dulbeco’s Modified Eagle’s Medium supplemented with 10% heat-inactivated FBS and 100 μg/mL amikacin and were maintained in humidified incubator at 37°C in 5% CO2-containing atmosphere. Sichuan University waived the requirement to obtain ethical approval for using the rat C6 glioma and human U251 glioma commercialized cell lines.

Male Sprague Dawley rats and female nude BALB/c mice (6–8 weeks old) were used for in vivo pharmacokinetic and antitumor test studies. The animals were purchased from the Laboratory Animal Center of Sichuan University, and were separately housed according to their sex at controlled temperature of 20°C–22°C, relative humidity of 50%–60%, and 12-hours light–dark cycles. Animals were provided with standard laboratory chow and tap water ad libitum. All the animals would be in quarantine for a week before treatment. All animal procedures were performed according to the protocol approved by the Institutional Animal Care and Treatment Committee of Sichuan University (Chengdu, People’s Republic of China). All mice were treated humanly throughout the experimental period.

Preparation of Cur/MPEG-PLA micelles

Cur/MPEG-PLA micelles were prepared by a self-assembly method. Cur (10 mg) and MPEG-PLA (90 mg) were codissolved in 5 mL acetone under stirring. The abovementioned
mixture was evaporated in rotary evaporator at 55°C using negative pressure. Subsequently, the resultant co-evaporant was dissolved in water. The solution was filtered by a syringe filter (0.22 μm) and then lyophilized and stored at 4°C before use.

**Characteristics of Cur/MPEG-PLA micelles**

Drug loading (DL) and encapsulation efficiency (EE) of Cur/MPEG-PLA micelles were determined as follows. Briefly, 10 mg of lyophilized Cur/MPEG-PLA micelles was dissolved in 0.1 mL of acetonitrile. The amount of Cur in the solution was determined by HPLC (LC-20AD; Shimadzu Corporation, Tokyo, Japan). The DL and EE of Cur/MPEG-PLA micelles were calculated according to the following equations:

\[
DL = \frac{\text{Drug}}{\text{Polymer + Drug}} \times 100\% \quad (1)
\]

\[
EE = \frac{\text{Experimental drug loading}}{\text{Theoretical drug loading}} \times 100\% \quad (2)
\]

The particle size and zeta potential of Cur/MPEG-PLA micelles were measured by dynamic light scattering. The 100 μL micelles were dissolved in 2 mL of distilled water (micelles concentration: 1 mg/mL), then the test was performed in triplicate.

The examination of transmission electron microscopy (TEM) samples followed the following procedures. In brief, the Cur/MPEG-PLA micelles solution was placed dropwise onto a copper grid. Approximately 15 minutes after nanoparticle deposition, the grid was tapped with filter paper to remove excess water and stained using a solution of phosphotungsten acid (2%, w/v) for 20 minutes. After the stained sample was allowed to air dry, TEM samples were obtained. A photomicrograph of Cur/MPEG-PLA micelles was obtained by using a transmission electron microscope (high-resolution transmission electron microscopy) (Tecnai G2 F20 S-TWIN).

Release of Cur from the Cur/MPEG-PLA micelles was performed by the dialysis membrane method. First, 1 mL of Cur/MPEG-PLA micelles solution (equivalent to 1 mg of Cur) was transferred in dialysis bags (Sigma-Aldrich Co.) with a molecular cutoff 3.5 kDa. The bags were suspended in 200 mL of phosphate-buffered saline (PBS) (pH 7.4) with 0.5% Tween 80 at 37°C in a shaking water bath at 100 rpm. At selected time intervals, 200 μL of normal saline (NS) sample was collected and replaced by an equal volume of fresh medium. The Cur content of PBS with Tween 20 was analyzed by an HPLC system.

**Pharmacokinetic**

Male Sprague Dawley rats (200±10 g body weight) were randomly assigned to two groups for pharmacokinetic investigation. Groups 1 and 2 received an intravenous (iv) injection of free Cur and Cur/MPEG-PLA micelles through the tail vein, respectively, at an equivalent dose of 60 mg/kg Cur versus the body weight. At time points of 0 (pre-dose), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-injection, 0.5 mL of blood was collected in heparinized polyethylene tubes via carotid artery and centrifuged at 1,000×g for 10 minutes to obtain plasma. The plasma was separated and extracted with ethyl acetate, and supernatant fluid was collected and evaporated to dryness. The dry residues were dissolved in methanol for HPLC analysis.

**MTT test**

The MTT assay was applied to determine the cell proliferation. The C6 and U251 cells were planted in 96-well plates containing FBS (3×10⁴ cells/well for 48-hour incubation and 5×10⁵ cells/well for 24-hour incubation). Then, the cells were treated with free Cur or Cur/MPEG-PLA micelles at different concentrations (50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 μg/mL, 3.125 μg/mL, 1.563 μg/mL, and 0.753 μg/mL). After incubation for 24 hours or 48 hours, 5 mg/mL of MTT solution was added. The cells were then incubated for 3 hours and combined with dimethyl sulfoxide. Formazan generated by cellular dehydrogenase was measured by IMARK microplate reader (Multiskan; Thermo Fisher Scientific, USA) at 570 nm of absorbance.

**Apoptosis study**

The apoptosis of C6 cells was assayed with flow cytometry (FCM, BD FACSCalibur). Briefly, C6 cells were seeded into six-well plates (3×10⁵ cells/well) and allowed to attach overnight. Then the cells were treated with free Cur or Cur/MPEG-PLA micelles at different concentrations for 24 hours (12.5 μg/mL, 6.25 μg/mL, and 3.125 μg/mL). Cells treated only with micelles were used as blank control. In the next step, the cells were harvested and combined with 5 μL Annexin V-fluorescein isothiocyanate (FITC) and 5 μL propidium iodide (PI) (Annexin V-FITC/PI Apoptosis Detection Kit). The stained cells were then analyzed with FCM.

**Cellular uptake**

Cellular uptake of free Cur and Cur/MPEG-PLA micelles was monitored by confocal microscopy and FCM. The C6 and U251 cells were grown in six-well culture plates...
PLA micelles were measured by immunochemistry with antibody Ki67 and CD31. Briefly, the tumor tissue frozen sections were fixed in acetone, washed with PBS, and stained with rabbit antirat Ki67 polyclonal antibody (1:50; BD Pharmingen™; BD Biosciences, San Jose, CA, USA) and rabbit antimouse CD31 (1:50; Abcam, Cambridge, UK). Then, it was washed twice with PBS, and stained with secondary antibody conjugating FITC or Rhodamine (Abcam). The positive cells were observed under microscope, and the number of capillaries per high-power field was manually counted.

**Statistical analyses**

The statistical analysis software SPSS15.0 for Windows (SPSS Inc., Chicago, IL, USA) was used. The results are recorded as mean ± standard deviation (SD). Analysis of variance was used for multiple group comparisons. \( P<0.05 \) was considered statistically significant.

**Results**

In this study, through the application of nanodelivery system, an aqueous formulation Cur/MPEG-PLA was obtained, and the anticancer activity and mechanism of this formation on glioma were explored in vitro and in vivo.

**Preparation and characterization of the Cur/MPEG-PLA micelles**

A highly soluble formation of Cur based on MPEG-PLA was developed by a single step of solvent evaporation method as previously reported. Cur and MPEG-PLA were codissolved in acetone, evaporated in rotary evaporator, and then combined with NS solution. During this process, Cur and MPEG-PLA self-assembled into Cur/MPEG-PLA micelles, which encapsulated Cur in the core part, with a hydrophilic shell as shown in Figure 1.

The developed Cur/MPEG-PLA micelles were further characterized with respect to particle size, polydispersity

---

**Notes:** The Cur/MPEG-PLA was prepared by a solvent evaporation method. The MPEG-PLA and curcumin with different proportions were codissolved in acetone. Then through the steps of evaporation and hydration, MPEG-PLA and curcumin self-assembled into Cur/MPEG-PLA micelles.

**Abbreviations:** Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; PEG, poly(ethylene glycol).
index, zeta potential, and appearance features. In Figure 2A, the size distribution spectrum showed that the Cur/MPEG-PLA micelles were monodispersed and had a very narrow particle size distribution (polydispersity index = 0.12 ± 0.03). These Cur/MPEG-PLA micelles showed an average diameter of ∼33 ± 2.3 nm in aqueous phase and had the DL of 9.85% ± 0.03% and EE of 98.5% ± 0.03%. According to Figure 2B, the zeta potential of Cur/MPEG-PLA micelles was −3.3 ± 0.3 mV. Furthermore, TEM was applied to observe the morphological characteristics of these nanoparticles. Spherical Cur/MPEG-PLA micelles were measured ∼23 nm in drying phase under electron microscope (Figure 2C). Since the structure of these amphiphilic particles was usually loose in solution, the size measured by dynamic light scattering was always a little larger than that measured by TEM.

As shown in Figure 2D, free Cur and Cur/MPEG-PLA micelles showed different dissolution behaviors in NS solution. Compared with free Cur, which formed a cloudy orange suspension (Figure 2Db), the Cur/MPEG-PLA micelle solution was transparent and clear, indicating a complete dispersibility in aqueous solution.

The in vitro release results showed that the Cur can be released slowly from Cur/MPEG-PLA micelles, and the free Cur was released very quickly (Figure 3A). The cumulative percentage release demonstrated that the amount of drug released from nanomicelles was gradually increased over time, and after 120 hours, there was an increase of >40%. The free Cur exhibited a high level (40%) at 2 hours. This indicated that Cur could be released from Cur/MPEG-PLA micelles.
To assess whether the micelles improve bioavailability of poorly water soluble drugs, the mean plasma concentration–time profiles of Cur after iv administration of free and formulated drug are presented in Figure 3B. Free Cur was rapidly cleared, and the plasma level of Cur was $<2.1 \mu g/mL$ of the injected dose within 5 hours of injection. Compared with free drug, Cur concentration in plasma was $\sim20$-fold higher for Cur/MPEG-PLA micelles at 6 hours after drug injection. The difference was most evident at time points beyond 6 hours (Figure 3B). The results demonstrate that MPEG-PLA-encapsulated Cur reduced drug elimination.

**Cur/MPEG-PLA micelles enhance antglioma cancer activity in vitro**

The anticancer activity of free Cur and Cur/MPEG-PLA micelles was studied in vitro. The MTT assay was applied to investigate the cytotoxicity on two glioma cell lines (C6 and U251). As shown in Figure 4, both free Cur and Cur/MPEG-PLA micelles have time- and dose-dependent inhibitive effects on cell viability of C6 and U251 cells. Compared with the 24-hour group, the cell viability of 48-hour group decreases more significantly at the same drug concentration. Meanwhile, the half maximal inhibitory concentration (IC$_{50}$) of Cur/MPEG-PLA micelles was slightly lower than that of free Cur, indicating that MPEG-PLA micelles improved the cytotoxicity of Cur to glioma cells.

The IC$_{50}$ of free Cur on U251 at 24 hours and 48 hours was 43.37 $\mu g/mL$ and 10.38 $\mu g/mL$, respectively, which was higher than that of Cur nanomicelles (24 hours: 29.02 $\mu g/mL$; 48 hours: 6.82 $\mu g/mL$). And IC$_{50}$ of free Cur on C6 at 24 hours and 48 hours was 4.74 $\mu g/mL$ and 1.97 $\mu g/mL$, respectively, which was higher than that of Cur nanomicelles (24 hours: 4.38 $\mu g/mL$; 48 hours: 1.57 $\mu g/mL$). These results indicated that the encapsulated Cur by MPEG-PLA could enhance the cytotoxic activity of Cur.

In addition, the intracellular uptake of free Cur and Cur/MPEG-PLA micelles was measured to explore the mechanism of increased toxicity and apoptosis effect. The inset in Figure 5 shows that in the Cur/MPEG-PLA micelle group, a very bright, greenish fluorescence was observed in C6 cells after 4-hour incubation, indicating an enhanced drug accumulation. In comparison, no fluorescence was found in the group treated with EM, and a weak fluorescence was observed in a few glioma cells in the free Cur group.

The apoptosis of C6 glioma cells induced by Cur and Cur/MPEG-PLA micelles was determined by FCM using Annexin V-FITC/PI staining. According to Figure 7, in the NS and EM groups, the glioma cell apoptosis rates were 2.48% and 1.98%. In the free Cur and Cur/MPEG-PLA micelle treatment groups, the cell apoptosis rates were 10.79% and 15.24% at the drug concentration of 3.125 $\mu g/mL$. At the drug concentration of 6.25 $\mu g/mL$, the cell apoptosis rates were 15.45% and 18.7%. And at the drug concentration of 12.5 $\mu g/mL$, the cell apoptosis rates were 20.51% and 51.22%. It is clear that Cur/MPEG-PLA micelles have more pronounced effects of inducing cell apoptosis compared with free Cur and control groups.

---

**Figure 3 Drug release in vitro and pharmacokinetic studies.**

**Notes:** (A) In vitro release study and (B) in vivo pharmacokinetics assay of free curcumin and Cur/MPEG-PLA micelles.

**Abbreviations:** Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; F-Cur, free curcumin; Cur-M, Cur/MPEG-PLA micelles; h, hours.
Nanomicelles improved antiglioma cancer activity of Cur in vivo

The nude mouse model bearing subcutaneous glioma was applied to evaluate the antiglioma activity of Cur/MPEG-PLA micelles. Four groups of randomly assigned mice bearing C6 tumor were treated with NS, EM, free Cur, and Cur/MPEG-PLA micelles through iv injection, respectively. Results shown in Figure 8 indicate that EM had no antiglioma activity, while free Cur and Cur/MPEG-PLA micelles could inhibit the growth of glioma. And the Cur/MPEG-PLA micelles inhibited glioma

Figure 4 In vitro cytotoxicity studies of Cur/MPEG-PLA micelles in different glioma cell lines. Notes: Increasing concentrations of free curcumin and Cur/MPEG-PLA micelles were added to U251 (A and B) and C6 (C and D) glioma cells. After 24 hours (A and C) or 48 hours (B and D) treatment, cells were harvested, and the extent of growth inhibition was measured by MTT assay. Abbreviations: Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; F-Cur, free curcumin; Cur-M, Cur/MPEG-PLA micelles.

Figure 5 (Continued)
Figure 5 C6 cell uptake drug assay.

Notes: Fluorescence microphotographs showing C6 cells treated with empty micelles (A and A₁), free curcumin (B and B₁), and Cur/MPEG-PLA micelles (C and C₁) at a concentration of 6.4 μg/mL after 4-hour incubation. Curcumin shows green fluorescence under fluorescence microscopy. A–C are bright-filed images and A₁–C₁ are fluorescence images.

Abbreviations: Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer.

Figure 6 (Continued)
Figure 6 Cell uptake drug assay with FCM.
Notes: FCM histograms showing cellular uptake of curcumin and Cur/MPEG-PLA micelles by C6 (A and B) and U251 (C and D) glioma cells at different drug concentrations after incubation for 4 hours. 3.2 μg/mL (A and C) and 6.4 μg/mL (B and D).
Abbreviations: FCM, flow cytometry; Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; NS, normal saline; EM, empty micelles; F-Cur, free curcumin; Cur-M, Cur/MPEG-PLA micelles.

Figure 7 The apoptosis of C6 glioma cells was determined by FCM using Annexin V-FITC/PI staining.
Notes: Normal saline (A), empty micelles (B), free curcumin (C–E), and Cur/MPEG-PLA micelles (F–H) were added to wells at different concentrations, respectively (Cur: 3.125 μg/mL for C and F, 6.25 μg/mL for D and G, and 12.5 μg/mL for E and H). After incubation for 24 hours, cells were harvested, stained with Annexin V-FITC/PI, and analyzed with FCM.
Abbreviations: FCM, flow cytometry; FITC, fluorescein isothiocyanate; PI, propidium iodide; Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer.
tumor growth more effectively than free Cur. More specifically, the weight of tumor in the Cur/MPEG-PLA micelle group was significantly lower than that in the group treated with free Cur, which suggested that the application of MPEG-PLA micelles enhanced the antiglioma activity of Cur in vivo.

In order to make clear the proliferative activity of glioma, the tumor sections of each group were stained with Ki67. The representative photographs were shown in Figure 9. The Ki67-positive tumor cells significantly reduced in the Cur/MPEG-PLA micelle group compared with that in other groups. The positive cells were counted, and the Ki67 index was significantly lower in the Cur/MPEG-PLA micelle group (27.2±3.5%) than that in groups treated with free Cur (43.1±5.9%), EM (67.2±7.3%), and NS (70.6±11.6%), indicating that Cur/MPEG-PLA micelles could obviously suppress the proliferation of glioma in vivo.

In addition, the TUNEL assay was applied to investigate the mechanism of the improved antiglioma activity of Cur/MPEG-PLA micelles. As shown in Figure 10, both free Cur and Cur/MPEG-PLA micelles treatment induced significant cellular apoptosis as compared with NS and EM treatment (P<0.05), which was revealed by greenish fluorescence. More apoptosis cells were observed in the Cur/MPEG-PLA micelle group than that in the NS, EM, and free Cur groups. The apoptosis index was significantly more in the Cur/MPEG-PLA micelle group (47.5±5.5%) than that in the NS (3.1±1.2%), EM (2.9±0.9%), and free Cur group (29.3±3.2%), which implied that the induction of cellular apoptosis could be a possible approach for Cur/MPEG-PLA micelles to induce antiglioma activity in vivo.

Furthermore, immunofluorescent analysis with anti-CD31 monoclonal antibody was performed to observe the
Figure 9 Cell proliferation activity assay with Ki67.

Notes: Ki-67 immunohistochemical staining applied for the assessment of tumor proliferation activity. Each group treated with NS (A and A₁), empty micelles (B and B₁), free curcumin (C and C₁), and Cur/MPEG-PLA micelles (D and D₁) was stained with Ki-67 antibody (A–D) and DAPI (A₁–D₁). Cur/MPEG-PLA micelles showed a pronounced antiproliferative activity compared with that of other groups.

Abbreviations: NS, normal saline; Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; DAPI, 4′,6-diamidino-2-phenylindole.
new vasculature content in frozen tumor sections. As shown in Figure 11, CD31-positive endothelial cells in the free Cur treatment group were less than that of the NS group and the empty micelle group but more than that of the Cur/MPEG-PLA micelle group (Figure 11A–D). The microvessel number was counted in details. A remarkably fewer of microvessels were present in the free Cur group (31±7) and the Cur/MPEG-PLA micelle group (14±3) compared with the NS group (131±23) and the EM group (120±17). In addition, the Cur/MPEG-PLA micelle group reduced the number of microvessels more significantly when compared with the free Cur group \(P<0.05\). No significant difference was observed between the NS group and the EM group.

**Discussions**

Cur has exhibited promising effects for treating cancer in various tissues.\(^8\)-\(^{11,24-27}\) It has received extensive attention with its unique effectiveness in glioma therapy. Previous studies demonstrated that Cur can significantly inhibit the proliferation of glioma cells by downregulating multidrug resistance proteins that cause the efflux of many chemotherapeutic agents.\(^{28,29}\) However, its clinical application is severely restricted due to its low water solubility.

In order to resolve the poor aqueous solubility, fast metabolism, and low biological availability of Cur, some materials were used such as liposomes and polymer micelles to improve it.\(^{16,30}\) Different aspects should be taken into account when selecting nanodelivery system, including suitable polymer fonts, support stability, chemotherapeutic drug solubility, and so on. As a biodegradable nanometer material, MPEG-PLA micelle has shown promising drug EE, high stability, and low toxicity in drug delivery in previous anticancer research.\(^{31-33}\) In this study, we used a biodegradable polymer MPEG-PLA to deliver Cur to the

---

**Figure 10** TUNEL test.

**Notes:** The TUNEL assay was performed for the detection of tumor cell apoptosis in glioma model. Tumor sections of each group treated with NS (A), empty micelles (B), free curcumin (C), and Cur/MPEG-PLA micelles (D) were stained with TUNEL for observation of cell apoptosis. Compared with free curcumin, Cur/MPEG-PLA micelles showed a prominent apoptosis induction effect.

**Abbreviations:** TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; NS, normal saline; Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer.
Biodegradable micelles enhance the antiglioma activity

Figure 11 Antiangiogenesis analysis with CD31 immunofluorescence staining.
Notes: Representative CD31 immunofluorescence images for the NS (A–A1), empty micelles (B–B1), free curcumin (C–C1), and Cur/MPEG-PLA micelles (D–D1) are shown. Groups were stained with CD31 antibody (A–D) and DAPI (A1–D1). Merged images are shown in (A2–D2).
Abbreviations: NS, normal saline; Cur, curcumin; MPEG-PLA, monomethoxy poly(ethylene glycol)-poly(lactide) copolymer; DAPI, 4′,6-diamidino-2-phenylindole.

Through a one-step solvent evaporation method, Cur was encapsulated into MPEG-PLA micelles to create Cur/MPEG-PLA micelles for better antiglioma effects. Compared with the preparation of Cur Poly (lactic-co-glycolide) (PLGA), the preparation of Cur-MPEG-PLA was very simple and fast. The Cur/MPEG-PLA assembly model has been demonstrated in Figure 1. Hydrophobic Cur exhibited a high affinity for the domain of PLA locating in the center of the spherical structure, resulting in a high encapsulation efficacy. And the MPEG segments located at the surface of this spherical structure were hydrophilic, which stabilized the Cur/MPEG-PLA micelles in water and prevented the aggregates of nanoparticles. With these characters, Cur/MPEG-PLA micelles can be fully dispersed in aqueous solution, which is consistent with the appearance of Cur/MPEG-PLA solution and the result of TEM in this study. Furthermore, this core–shell structure may contribute to the sustained drug release in vitro and the high effective treatment of glioma. Compared with the Cur loaded in the PLGA and PEG-PLGA, Cur PLA-PEG nanomicelles have a small particle size, high DL, and high EE.

Although Cur-encapsulated formulations have been made in the recent past, their effectiveness has been limited due to their high particle size and low penetrating capacity into the cancer cells, resulting in poor therapeutic effects in cancer treatment. In a previous study, the gaps between adjacent endothelial cells were >200 nm. The micelles loading drug with diameter <200 nm could pass through the endothelial cell gaps into tumor tissues. The Cur/MPEG-PLA micelles prepared by our group in this work were monodispersed and showed an average diameter ∼33±2.3 nm in aqueous phase, which made Cur/MPEG-PLA micelles cross the endothelial cell gaps smoothly so as to improve the antiglioma activity of Cur.

From the pharmacokinetic experiment, we found that the circulation time of Cur nanoformulations in vivo was prolonged, which indicated that the biocompatibility and bioavailability of Cur nanoformulations can be increased, with the same advantages of other Cur formulations. With the encapsulation of MPEG-PLA micelles, Cur was more easily taken up by glioma cells and reached a higher concentration in C6 and U251 cell lines compared with free...
Cur, which was demonstrated in Figures 5 and 6. In this study, since the results of MTT assay showed that the cell viability of C6 and U251 cell lines in the Cur/MPEG-PLA micelle group decreased more significantly, we speculate that the high drug uptake of Cur/MPEG-PLA micelles in glioma cells may contribute much to the enhanced antiangioma activity in vitro. For testing uptake of Cur through FCM, we found that glioma cell features of uptaking of more Cur from Cur nanoparticles was similar to the nanoparticulate Cur made by Mohanty and Sahoo and Trippo.37

In the nude mouse model bearing glioma, our study showed that the weights and volumes of subcutaneous gliomas were more effectively inhibited in the Cur/MPEG-PLA micelle group compared with other groups. In the meanwhile, the body weights of nude mice in four groups were not statistically significant, indicating a low drug toxicity of Cur/MPEG-PLA micelles to normal tissues. The result of pharmacokinetic study in our research exhibited a more stable plasma concentration of Cur released from Cur/MPEG-PLA micelles, which may be due to the avoidance of elimination of Cur in circulation through encapsulation by MPEG-PLA micelles. Moreover, the sizes of Cur/MPEG-PLA micelles are smaller than the tumor interendothelial junctions. Combined with the impaired lymphatic drainage, the localization of Cur/MPEG-PLA micelles is much improved. As we all know, prolonged accumulation of chemotherapy agents in the tumor region is crucial for effective chemotherapy.

The antitumor mechanisms of Cur were explored in this research. It is known that the nuclear-associated antigen Ki67 is expressed in proliferating cells. Previous studies have shown that Ki67 is closely related to the activity of cell proliferation and could be a predictor of prognosis of various tumors.48,49 As shown in Figure 9, the Ki67-positive cells in the Cur treatment groups were much fewer than the control groups, indicating that Cur inhibited glioma through the inhibition of cell proliferation. In addition, tumor sections were stained with CD31 to evaluate the angiogenesis of glioma. The number of microvessels in each group was counted. It was obvious that the Cur treatment led to a marked inhibition of angiogenesis in tumor tissues, which suggested that the mechanism of antiangiogenesis may be involved in the inhibition of glioma by Cur in vivo. Furthermore, the apoptosis tumor cells were also examined in vitro and in vivo. The results of Annexin V-FITC/PI staining in vitro and TUNEL staining of tumor sections were consistent. According to the results shown in Figures 7 and 10, induction of apoptosis may be another mechanism that Cur inhibits glioma. More importantly, the glioma cell apoptosis rate of the Cur/MPEG-PLA micelle group was higher than that of the free Cur group, which implied that MPEG-PLA micelles enhanced the antiangioma activity of Cur.

**Conclusion**

Biodegradable Cur/MPEG-PLA micelles were applied to treat glioma cancer in vitro and in vivo. Compared with free Cur, the cellular uptake and cytotoxicity were increased in vitro after Cur was encapsulated into polymeric micelles. Besides, a sustained release behavior was observed in the Cur/MPEG-PLA micelle group in vitro. Furthermore, Cur/MPEG-PLA micelles showed significant effectiveness on suppressing glioma growth by inducing more cell apoptosis and inhibiting more cell proliferation and angiogenesis versus free Cur. Thus, the Cur/MPEG-PLA micelles in this study may have potential clinical applications in glioma therapy.

**Acknowledgment**

This work was supported by the National Natural Science Foundation of China (NSFC81502165) and Sichuan University Outstanding Young Scholars Research Fund (2016SCU04A04).

**Disclosure**

The authors report no conflicts of interest in this work. The authors alone are responsible for the content and writing of the paper.

**References**

1. Jones C, Baker SJ. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. *Nat Rev Cancer*. 2014;14(10):651–661.
2. Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. *Nat Rev Neurosci*. 2014;15(7):455–465.
3. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. *Nat Rev Neurol*. 2009;5(11):610–620.
4. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature*. 2012;483(7390):479–483.
5. Xi G, Hayes E, Lewis R, et al. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro. *Oncogene*. 2016;35(2):241–250.
6. Tan B, Li Y, Zhao Q, et al. Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway. *Cancer Gene Ther*. 2014;21(12):526–531.
7. Stedt H, Samarayanake H, Pikkarainen J, et al. Improved therapeutic effect on malignant glioma with adenosine suicide gene therapy combined with temozolomide. *Gene Ther*. 2013;20(12):1165–1171.
8. Milacic V, Banerjee S, Landis-Piwowar KR. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. *Cancer Res*. 2008;68(18):7283–7292.
9. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clin Cancer Res*. 2005;11(20):7490–7498.
10. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*. 2008;14(14):4491–4499.
11. Kunnumakkara AB, Guha S, Krishnan S, Diagaradipane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. *Cancer Res.* 2007;67(8):3853–3861.

12. Zanotto-Filho A, Braganhol E, Schröder R, et al. NFXB inhibitors induce cell death in glioblastomas. *Biochem Pharmacol.* 2011;81(3):412–424.

13. Zanotto-Filho A, Braganhol E, Edelweiss ML, et al. The curcry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. *J Nutr Biochem.* 2012;23(6):591–601.

14. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. *Trends Pharmacol Sci.* 2009;30(11):592–599.

15. Singh S, Dash AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. *Crit Rev Ther Drug Carrier Syst.* 2009;26(4):333–372.

16. Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. *Biomaterials.* 2010;31(20):5436–5444.

17. Kim BY, Rutka JT, Chan WC. Nanomedicine. *N Engl J Med.* 2010;363(25):2434–2443.

18. Mista R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. *Drug Discov Today.* 2010;15(19–20):842–850.

19. Gong C, Wang C, Wang Y, et al. Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites. *Nanoscale.* 2012;4(10):3095–3104.

20. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev.* 2011;63(3):136–151.

21. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. *Bioconjug Chem.* 2010;21(5):797–802.

22. Gao X, Wang B, Wei X, et al. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. *Nanoscale.* 2012;4(22):7021–7030.

23. Gao X, Zheng FJ, Guo G, et al. Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles. *J Mater Chem B.* 2013;1:5778–5790.

24. Poole KM, Nelson CE, Joshi RV, et al. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease. *Biomaterials.* 2015;41:166–175.

25. He GL, Liu Y, Li M, et al. The amelioration of phagocytic ability in cancer cells by quercetin. *Biochem Pharmacol.* 2016;101:353–360.

26. Gao Y, Li Z, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. *Drug Dev Ind Pharm.* 2010;36(10):1225–1234.

27. Tripodo G, Pasut G, Trapani A, et al. Inulin-D-alpha-tocopherol succinate (INVITE) nanomicelles as a platform for effective intravenous administration of curcumin. *Biomacromolecules.* 2015;16(2):550–557.

28. Sun J, Bi C, Chan HM, Sun S, Zhang Q, Zheng Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. *Colloids Surf B Biointerfaces.* 2013;111:367–375.

29. Zou P, Helsen L, Maitra A, Stern ST, McNeil SE. Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. *Mol Pharm.* 2013;10(5):1977–1987.

30. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin: influence of preclinical studies on its oral bioavailability. *Biomaterials.* 2010;31(25):6597–6611.

31. Tripodo G, Chilapanidas T, Perteghella S, et al. Mesenchymal stromal cells loaded curcumin-INVITE-micelles: a drug delivery system for neurodegenerative diseases. *Colloids Surf B Biointerfaces.* 2015;125(0):300–308.

32. Miconi G, Palumbo P, Dehordi SR, et al. Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcome. *J Cell Biochem.* 2015;116(5):864–876.

33. Laurinavicius A, Green AR, Laurinaviciene A, et al. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. *Oncotarget.* 2015;6(38):41134–41145.
